750 Million GM Mosquitoes Will Be Released in the Florida Keys

There have been no reports of health or environmental harm in other locations where genetically modified mosquitoes have been introduced over the last decade.

Written byLisa Winter
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

ABOVE: © ISTOCK.COM, 3DFOX

With the aim of reducing rates of the mosquito-borne illnesses yellow fever and dengue, a pilot program will release 750 million genetically modified mosquitoes into the Florida Keys in 2021, thanks to approval by the barrier islands’ Mosquito Control District Board of Commissioners at a meeting on Tuesday (August 18).

The strain of GM mosquitoes, known as OX513A, is an altered form of Aedes aegypti created by UK-based biotech firm Oxitec. Released mosquitoes will be all male, as male mosquitoes do not bite and generally only feed on nectar. Thanks to a conditionally lethal genetic variant, when OX513A mosquitoes mate with wild females, their offspring should die before they are old enough for females to begin biting.

Over the last 10 years, Oxitec deployed these GM mosquitoes in the Cayman Islands and Brazil. This will be the first release of any GM mosquitoes in the US. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Lisa joined The Scientist in 2017. As social media editor, some of her duties include creating content, managing interactions, and developing strategies for the brand’s social media presence. She also contributes to the News & Opinion section of the website. Lisa holds a degree in Biological Sciences with a concentration in genetics, cell, and developmental biology from Arizona State University and has worked in science communication since 2012.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies